NCT04637048|UnknownDMC
Loading search results
Sponsor study identifier
observational
1,000
1 country
1
Study Start
February 16, 2017
Actual (reported)Primary Completion
December 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, the patient with hepatobiliary tumors even accepted radical surgery, the postoperative recurrence rate is still high. Therefore, it is of great significance to find important prognostic markers to improve patient prognosis and formulate new treatment plans. In recent years, targeted therapy and immunotherapy make cancer treatment enter a new field, However, tumor heterogeneity is the greatest challenge in cancer therapeutics and biomarkers discovery. In this study, we collected a wide rang of patients' information, including photos of patients' face, physical strength and nutrition indicators, blood ,stool and pathological tissue specimens from tumor patients, then Multi-omics testing were applied to Looking for novel therapeutic targets and prognostic markers to predict patient response to treatment. Clinicians choose the best treatment plan for the patient based on the test results to improve the patient's survival time and quality of life.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 16, 2017
Actual (reported)November 14, 2020
Actual (reported)November 19, 2020
Actual (reported)December 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Evaluate the overall survival rate of all patients with hepatobiliary tumor
In order to identify the potential influence factors of hepatobiliary tumor patients survival
5 years
Evaluate the recurrence free survival rate of patients with hepatobiliary tumor
5 years
Evaluate the cancer-specific survival rate of patients with hepatobiliary tumor
5 years
Patients diagnosed and treated as hepatobiliary tumors and other alimentary tract tumors
Gang Chen
Wenzhou, Zhejiang, 325000, China
Yang J, Wang D, Ma L, An X, Hu Z, Zhu H, Zhang W, Chen K, Ma J, Yang Y, Wu L, Chen G, Wang Y. Sarcopenia negatively affects postoperative short-term outcomes of patients with non-cirrhosis liver cancer. BMC Cancer. 2023 Mar 6;23(1):212. doi: 10.1186/s12885-023-10643-6.
normal tissue, tumor samples, blood, urine, feces, ascites, bile samples
Gang Chen, M.D.
First Affiliated Hospital of Wenzhou Medical University
First Submitted
November 14, 2020
First Posted
November 19, 2020
Study Start
February 16, 2017
Actual (reported)Primary Completion
December 1, 2023
Estimated (date passed)Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
Evaluate the Progression Free Survival rate of patients with hepatobiliary tumor
5 years
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
June 16, 2022
Record last verified: 2022-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: